News & Events

Confo Therapeutics to present at Cowen 40th Annual Health Care Conference

Confo Therapeutics to present at Cowen 40th Annual Health Care Conference

Ghent, Belgium, 27 February 2020 – Confo Therapeutics, a pioneering biopharma company, today announces that Cedric Ververken, CEO, will present at the Cowen 40th Annual Health Care Conference on Tuesday, March 3, 2020 at 3:00 p.m. ET in Boston, MA.

Confo Therapeutics is also available for 1x1 meetings at the event. Investors interested in meeting with the Company should contact the conference coordinator. The conference is taking place from March 2-4 2020, at the Boston Marriott Copley Place.

For more information on the conference, see the website:

About Confo Therapeutics

Confo Therapeutics is a pioneering biopharmaceutical company building a portfolio of transformative medicines for the treatment of serious diseases using its proprietary Confo® technology, a proprietary GPCR conformation-sensitive drug discovery engine.

Confo Therapeutics’ unique approach presents G protein-coupled receptors (GPCRs) in the conformation of interest. This increases screening sensitivity and enables the determination of the 3D structure of the relevant conformation, allowing for the identification of novel chemical starting points and the rational design of new medicines with optimal properties.

As well as developing its own pipeline, Confo Therapeutics has secured revenue-generating drug discovery partnerships with select leading pharma companies (Lundbeck, Roche).

Confo Therapeutics was spun out of Vrije Universiteit Brussel (VUB) and Vlaams Instituut voor Biotechnologie (VIB) in 2015 and has since raised over €36.7 million from an international investor syndicate (BioGeneration Ventures, Capricorn Partners, Fund+, MINTS, Perceptive Advisors, PMV, QBIC, V-Bio Ventures, VIB and Wellington Partners). The company is headquartered in Ghent and has a second operational site in Brussels.

For more information, visit:
Connect with us on LinkedIn:

Issued for and on behalf of Confo Therapeutics by Instinctif Partners.
For more information please contact:


back to news